Compare Synopsys, Inc. (SNPS) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Teladoc Health Inc — how do they compare? Synopsys, Inc. trades at $398.2 (market cap $75.13B), while Teladoc Health Inc trades at $6.09 (market cap $1.14B). The key difference: Synopsys, Inc. is far larger — about 65.9× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SNPS | TDOC | |
|---|---|---|
Market Cap | $75.13B | $1.14B |
Sector | Technology | Health |
52-Week High | $534.56 | $9.72 |
52-Week Low | $372.33 | $4.47 |
Enterprise Value | $82.36B | $1.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.
The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Analyst consensus is a hold with a $8.88 price target, while recent news highlights leadership changes and ongoing legal investigations.
The outlook is cautious; while valuation ratios like P/S of 0.45 and EV/EBITDA of 6.5 appear attractive, persistent losses and negative ROE of -12.99% pose risks. Upside depends on profitability improvements under new CFO Michael Grasher, but investor sentiment is tempered by weak earnings and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
